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The main aim of this study was to develop a multiparticulate system containing mini-tablets of omeprazole 
formulated with an enteric polymer with pH-dependent solubility. Pre-formulation studies showed good 
flow and compaction capacity, leading to the production ofhigh quality mini-tablets. The mini-tablets 
were coated in a fluidized bed with hydroxypropylmethylcellulose /Eudragit® L30D55 and packed into 
hard gelatin capsules. The dissolution profile showed gastro-resistance and zero-order kinetics. The 
dissolution profile for the formulation containing lactose as the diluent and coated with 12% (tablet 
weight gain) of polymer was similar to that ofthe reference drug.
Uniterms: Multiparticulate system/modified release. Enteric release mini-tablets/development. Enteric 
release mini-tablets/evaluation. Omeprazole/dissolution.
O presente trabalho teve como objetivo desenvolver e avaliar um sistema multiparticulado de liberação 
modificada, composto por mini-comprimidos revestidos com polímero de liberação pH-dependente, 
utilizando como fármaco modelo o omeprazol. Os mini-comprimidos (diâmetro de 2,5 mm) foram obtidos 
em máquina de compresssão excêntrica, revestidos em leito fluidizado com hidroxipropilmetilcelulose/
Eudragit®L30D55 e, em seguida, acondicionados em cápsulas gelatinosas duras. A partir dos resultados 
obtidos no perfil de dissolução foi possível demonstrar a liberação gastro-resistente e comportamento 
cinético de ordem zero. A formulação contendo lactose como diluente, com revestimento de 12% de 
polímero, demonstrou semelhança com o medicamento referência.
Unitermos: Sistema multiparticulado/liberação modificada. Mini-comprimidos de liberação entérica/
desenvolvimento. Mini-comprimidos de liberação entérica/avaliação. Omeprazol/dissolução.
INTRODUCTION
The solid dosage forms of drugs for oral use are 
marketed all over the world and are classified according 
to their drug release behavior as conventional or modified 
release (Ashford, 2005; Allen, Popovich, Ansel, 2013)
The modified-release dosage forms are designed as 
monolithic or multiparticulate systems, and their function 
is to modify the bioavailability of the drug and extend the 
release or control the beginning of the drug dissolution 
in the gastrointestinal tract(Costa, Lobo, 1999; Lee, 
Robinson, 2000; ANVISA, 2010).
In a monolithic system the total administered drug is 
concentrated in a single release unit (tablet, coated tablet 
or hard gelatin capsule). In contrast, in multiparticulate 
forms the drug is divided into several functional subunits, 
such as granules, pellets or mini-tablets (coated or not), 
contained within a final dosage form (tablet or softgel) 
that disintegrates rapidly after administration releasing 
the subunits into the gastrointestinal tract. This reduces the 
risk of a high local drug concentration and the potential 
effect of localized irritation of the gastric mucosa (Ghebre-
Sellassie, Knoch, 2002; Pezzini, Silva, Ferraz, 2007).
In order to optimize the multiparticulate system, the 
subunits that comprise it can be coated to protect the drug, 
to mask the taste and/or odor, to protect against digestive 
fluids (enteric coating) or to control the drug release 
(Aulton, 2005; Pezzini, Silva, Ferraz, 2007).
Mini-tablets are tablets with a diameter equal to or 
less than 3 mm, obtained in a conventional compressor 
machine using punches of single or multiple punch presses, 
with direct compression being the most suitable method, 
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especially in the case of drugs with sensitivity to humidity 
and/or temperature, when the formulation demonstrates 
appropriate flow and compression properties. Other 
compression techniques can also be used but due to the 
larger numbe rof operations required these methods are not 
as attractive (Rouge et al., 1997; Lennartz,Mielck, 2000)
Omeprazole (OMP) is a lipophilic drug, which 
behaves as a weak base and it is moderately soluble 
in alcohol and slightly soluble in water (pKa1=4.2 and 
pKa2=9.0). In aqueous solution at 25 °C there is the 
complete formation of a precipitate at pH = 2.2 to 4.0 and 
at pH = 11 the drug degrades in less than 4 hours (Mathew, 
Gupta, Bailey, 1995; Riedel, Leopold, 2005).
In the preparation of medicinal products for oral use 
it is therefore important to consider using a protective layer 
comprised of a gastro-resistant polymer to maintain the 
integrity of omeprazole, thereby preserving its therapeutic 
activity (Bruntonet al., 2008;Nair et al., 2010).
In this context, the main objective of this study 
was to develop and evaluate a multiparticulate modified-
release system, containing mini-tablets of omeprazole 
coated with a polymer with pH-dependent solubility.
MATERIAL AND METHODS
The pharmaceutical materials were kindly supplied 
by the pharmaceutical laboratory Prati Donaduzzi and 
used as received.
Preparation of mini-tablets
Two formulations were prepared (Table I). The size 
of the raw materials was standardized using a 40 mesh 
sieve and the materials were then mixed for 15 minutes in 
the BIN mixer at 15 rpm. The compacted bulk density of 
the mixtures obtained was evaluated in triplicate (SVM121 
Erweka). The values obtained were used to determine the 
Hausner factor (HF) according to the procedure described 
in USP, 2010.
Evaluation of mini-tablets
Hardness
The hardness of the mini-tablets produced was 
determined in a TBH ERWEKA® hardness tester using 10 
mini-tablets of each formulation (Farmacopéia brasileira, 
2010).
Friability
A dust-free sample (3g) of mini-tablets was 
accurately weighed and analyzed in a tablet friability 
apparatus (Erweka® GmbH, Bizen, Germany) with 200 
glass beads. The percentage of friability was calculated 
considering the initial weight (Thoma, Ziegler, 1998).
Weight Variation
Twenty mini-tablets were weighed individually in 
an AG200 analytical balance (Gehaka, São Paulo, Brazil) 
and the mean and coefficient of variation were determined.
Coating of mini-tablets
Batches of formulations A and B (mini-tablets 100g) 
were coated in a fluidized bed (LM-FBD 5.0/Wuster, 
Labmac, Sao Paulo, Brazil) with an air inlet temperature 
of 40 °C and an initial flow of 2.5 mL.min-1 followed by 
10 min at 4 mL.min-1. The insulating layer of 4% (w/v) 
aqueous hydroxypropyl methylcellulose (HPMC) was 
applied until a weight gain of 3% was achieved. After 
this treatment, the mini-tablet batches were covered with 
an enteric coating, employing the same equipment and 
conditions, using an aqueous dispersion of Eudragit® 
L30D55, talc, triethyl citrate and titanium dioxide, to 
give weight gains of 8, 10 and 12%. These batches were 
evaluated employing the dissolution test (acid phase) to 
determine the minimum effective coating, considering 
the amount of polymer that provides an OMP release of 
< 10%.
Preparation of multiparticulate dosage form
Multiparticulate systems were prepared in hard 
gelatin capsules (size 3), encapsulating in each one around 
200 mg of mini-tablets (equivalent to 20 mg of OMP). 
The samples containing uncoated mini-tablets were 
TABLE I - Formulation of mini-tablets containing omeprazole
Raw material Formulation A (%) Formulation B (%)
Omeprazole 11.98 11.98
Microcrystalline 
cellulose
73.65 -
Spray-dried lactose - 73.65 
Magnesium 
carbonate
1.20 1.20 
Colloidal silicon 
dioxide
0.6 0.6
Hydrogenated 
vegetable oil
4.19 4,19
Sodium starch 
glycolate
5.99 5.99
Sodium lauryl 
sulfate
2.39 2.39
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TABLE II – Characterization of mini-tablets produced
Analysis Formulation A Formulation B Limits
Friability (%) 0.34 0.45 <1.5
Hardness (kgf) 6.2 ± 0.4 6.3 ± 0.3 ≥ 3
Mean Weight (mg) 12.35 ± 0.34 12.40 ± 0.36 -
Concentration (% w/w) 11.89 ± 0.19 11.95 ± 0.17 11.37 ≤ R ≤ 12.57
denominated as systems A and B (Table I). Also, they were 
referred to as 1 or 2 according to the amount of coating 
required to meet the minimum effective coating (10 or 
12% of tablet weight, respectively).
The samples were thus named as follows: formulation 
A1 (with 10% of weight gain); A2 (with 12 % of weight 
gain); formulation B1 (with 10% of weight gain) and B2 
(with 12% of weight gain).
Determination of omeprazole in uncoated and coated 
mini-tablets
The  con ten t  o f  OMP in  t he  min i - t ab l e t s 
w a s  d e t e r m i n e d  b y  h i g h  p e r f o r m a n c e  l i q u i d 
chromatography (HPLC) according to the United States 
Pharmacopoeia(United States, 2010).
Dissolution profile of the multiparticulate dosage forms
The reference sample (REF)and the systems A, B, 
A1, A2 , B1 and B2 were evaluated in a Varian dissolution 
apparatus (paddle), at a speed of 100 rpm and temperature 
of 37 ºC±0.5 °C. The dissolution test was conducted 
at 150 min, divided into two steps. The first step was 
performed in 120 min using 0.1 M hydrochloric acid 
(500 mL) with a 10 mL sample removed at the end of the 
step. In the second step (30 min) 400 mL of 0.235 M dibasic 
potassium phosphate buffer was added to the dissolution 
medium and the pH was adjusted to 6.8. Samples (10 mL)
were removed at 125, 130, 135, 140 and 150 min after the 
start of the test. The dissolved drug content was evaluated 
by HPLC (United States Pharmacopoeia, 2010).
For the uncoated mini-tablets (A and B) the 
dissolution was evaluated without passing through the 
first step to prevent the acid decomposition of OMP. 
The comparison between the dissolution profiles was 
performed by analysis of the difference (f1)/similarity 
(f2) factors and the dissolution efficiency (DE). The 
comparison between the DE values was performed by 
analysis of variance (ANOVA - single factor) with a 
significance level of 5% (Khan, 1975; Marcolongo, 2003).
Study on OMP release kinetics
To identify the most suitable kinetic model to 
describe the drug release from the multiparticulate system 
developed zero-order, first-order and Higuchi (or pseudo-
zero-order)equations were used (Jug, Becirevic-Lacan, 
2004).
RESULTS AND DISCUSSION
Evaluation of mixtures and mini-tablets obtained
The Hausner factor (HF) was used to predict 
the flow properties of the powder mixtures, since this 
measurement is closely related to the friction between 
the particles of the mixture. Both formulations showed 
good flow properties represented by their HF values of 
1.20 (for A) and 1.17 (for B), and thus the mini-tablets (A 
and B) could be obtained by direct compression (Aulton, 
2005).
Characterization of uncoated mini-tablets
Table II shows the results obtained for the uncoated 
mini-tablets (cores). The parameters were adapted to the 
specifications of the monograph for tablets given in the 
Brazilian Pharmacopoeia 2010. The hardness values of 
>3.5Kgf, the good results obtained in the friability test 
and the non-occurrence of capping, cracks or lamination 
demonstrated the mechanical strength of the cores (Wu 
et al., 2008). The omeprazole contents were determined 
by HPLC and were in agreement with the compositions 
detailed in Table I.
Minimum effective amount of enteric coating
Batches of mini-tablets coated with appropriate 
amounts of polymer to give 10% and 12% weight gain 
were dissolved by less than 10% after a 120-min test in 
acid medium, confirming the gastric resistance within the 
specified pH range.
The multiparticulate dosage forms were prepared 
in hard gelatin capsules with batches of mini-tablets of 
formulations A and B with coating levels of 10 or 12% and 
designated as 1 and 2 (i.e., A1, A2, B1, B2), respectively. 
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The composition of each formulation corresponds to 
around 200 mg of mini-tablets(equivalent to 20 mg of 
OMP)in accordance with the content of omeprazole 
determined by high performance liquid chromatography 
(HPLC) and described in Table III.
All samples evaluated presented different 
omeprazole contents according to their formula and this 
value serves as a reference for determining the level of 
coating required. For the coated batches, the omeprazole 
content decreased as the level of coating applied increased. 
Thus, a higher drug content indicated a lower level of 
coating (Amighi, Moes, 1996).
Dissolution profile of the reference product
The dissolution profile of the reference drug showed 
pH-dependence, consistent with retarded drug release 
(Figure 1).
The release of OMP from capsules containing 
mini-tablets is regulated by the system reservoir. 
After dissolution of the coating, the pharmaceutical 
formulation was rapidly dissolved. The typical sigmoid 
shape of the curve indicates that the disintegration and 
dissolution are comparable. The behavior under different 
pH conditions was consistent with that expected, that is, 
no release at pH 1.0 and rapid release in pH 6.8 (Maganti, 
Elik, 1994).
Dissolution profile of the formulations prepared
The encapsulated mini-tablets (A and B)showed 
more than 90% of drug release after 10 min of testing 
in phosphate buffer pH 6.8 (Figures 2 and 3), behaving 
as an immediate-release dosage form. This behavior 
was expected, since the compositions do not include 
components that modify the release process.
The multiparticulate systems A1, A2, B1 and B2 
(Figures 2 and 3) showed pH-dependent dissolution 
profiles with the dissolution of the drug beginning after 
changing the dissolution medium to pH 6.8 (120 min) with 
the release reaching over 90% after 150 min of testing. 
This behavior was also expected, since the gastro-resistant 
polymer coating was derived from methacrylic acid 
(Eudragit® L30D55), which dissolves at pH >5.5 (Chuong, 
Christensen, Ayres, 2008).
The dissolution of < 1% at acidic pH showed that the 
polymer coating provided good control of the drug release 
at the two levels of coating evaluated (10% and12%, by 
weight), but the mini-tablets with a higher amount of 
polymer used in the coating (12%) showed more effective 
control.
Comparison of dissolution profiles
A comparative evaluation of the dissolution profiles 
(Figure 1, 2 and 3) is useful in the selection of formulations 
TABLE III - Result for contents and average weight of coated mini-tablets of omeprazole
Analysis A1  A2 B1 B2
Mean Weight (mg) 14.18 ± 0.42 14.52 ± 0.29 14.17 ± 0.54 14.58 ± 0.44
Concentration (% w/w) 10.24 ± 0.15 10.05 ± 0.20 10.29 ±0.14 10.07 ±0.18
FIGURE 1 – Reference omeprazole released (%) in the 
dissolution test (n=18).
FIGURE 2 - Drug release profiles of formulations A, A1 and 
A2 (n=18).
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TABLE IV - Results for f1, f2 and DE% of capsules containing 
coated mini-tablets
Samples f1 f2 DE (%)
Reference 56.73 ± 3.44
A1 3.63 76.20 59.66 ± 0.74
A2 10.25 57.21 52.83 ± 0.67
B1 10.22 56.29 64.41 ± 1.15
B2 2.96 79.83 57.3 ± 1.00
TABLE V - Dissolution efficiency (%) in comparison with 
reference using ANOVA
Fcalculated F Results
A1 5.5421 4.6001 Different
A2 9.8165 Different
B1 35.81 Different
B2 0.2229 Similar
TABLE VI - Study on release kinetics
Formulation Zero-order First-order Higuchi
A1 0.9218 0.9584 0.9154
A2 0.9465 0.9391 0.8711
B1 0.9005 0.9611 0.9409
B2 0.9465 0.9458 0.9170
Reference 0.9246 0.9657 0.9109
FIGURE 3 - Drug release profiles of formulations B, B1 and 
B2 (n=18).
during the processes related to pharmaceutics and also to 
establish the similarity between a new general formula 
and its reference (Moore, Flanner, 1996; Adams et al., 
2001).
A comparison of the dissolution profiles using 
the factors f1 and f2 (Table IV) demonstrated that all 
formulations had dissolution profiles similar to that of the 
reference drug (ANVISA, 2010).
The dissolution efficiency (DE%; Table IV) is an 
important parameter of the release kinetics and it allows 
the comparison of two formulations (Costa, Lobo, 1999). 
For a more detailed assessment, the dissolution study was 
accompanied by statistical analysis to infer the similarity 
between the dissolution profiles obtained. The analysis of 
variance (ANOVA) results showed that only the capsule 
containing B2 mini-tablets (Table V) showed a DE% 
similar to the reference drug. However, assessment of the 
formulation by determining the DE% is not addressed by 
pharmaceutical regulatory agencies.
The results revealed that the different methods used 
to compare dissolution profiles can lead to antagonistic 
results. However, the application of these methods can 
provide more accurate information on the dissolution 
behavior of products, facilitating the development or 
optimization of formulations.
The quantitative interpretation of the values 
obtained for the dissolution profiles, based on the 
percentage dissolved versus time, is facilitated by the 
use of mathematical models (Marcolongo, 2003; Kumar, 
Tewari, 2006).
In this study, three mathematical models were 
applied for the interpretation of the dissolution kinetics: 
zero-order, first-order and the Higuchi model. The 
kinetics models were evaluated through the linearization 
of the profile data according to the dissolution time and 
percent drug released. To select the most suitable model 
the coefficient of correlation (r) is calculated, to identify 
which model most closely approaches perfect linearity. 
The results for the linearization of the data are shown in 
Table VI.
The correlation coefficients for the formulations 
showed different release kinetics. The A2 and B2 mini-
tablets presented zero-order release kinetics profiles, 
indicating that the release occurs independently of the 
amount of drug remaining, due to excess coating being 
employed, which delayed the early release.
The formulations A1 and B1 showed first-order 
release kinetics, where the amount of drug released versus 
time is dependent on the amount of drug remaining in 
the formulation, this being the model that best fits the 
immediate-release formulations, in agreement with 
descriptions in the literature (Cid, 1981).
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CONCLUSIONS
The mini-tablets containing omeprazole prepared by 
direct compression presented smooth edges and uniform 
color and were able to support the coating processes. 
Coating of the mini-tablets with 10% (in terms of weight 
gain) of methacrylic polymer was sufficient to obtain the 
desired gastro-resistance.
The proposed formulations showed good flow 
properties (Hausner factor) for formulations A and B, 
respectively. The produced uncoated mini-tablets meet the 
requirement for specifications of the monograph for tablets 
given in the Brazilian Pharmacopoeia (2010).
The dissolution profiles of the tablets produced 
indicated good control of the release of the drug by the 
polymer coating at the two levels evaluated, indicating that 
the methacrylic derivative used is suitable for obtaining 
delayed-release systems. For the comparative analysis 
of the dissolution profiles based onf1 and f2, all capsules 
produced showed similarity to the reference product. 
Only capsules containing the mini-tablets B2 showed 
dissolution profiles similar to the reference drug, according 
to single factor ANOVA.
The first-order kinetics model was found to be most 
suitable to represent the release profiles of omeprazole 
multiparticulate systems A1 and B1 and the reference 
drug whereas the zero-order model was best suited for 
systems A2 and B2.
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